Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis

Neurology

Volumn 53, Issue 9, 1999, Pages 2093-2096

  Metz, Luanne M ^a,c   Sabuda, D ^c   Hilsden, R J ^b   Enns, R ^b   Meddings, J B ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

Corticosteroids; Gastric permeability; MS; Peptic ulcer disease

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEARTBURN; HUMAN; INSOMNIA; INTESTINE MUCOSA PERMEABILITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0032787062     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.9.2093     Document Type: Article

References (23)

1. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581-588.
2. Barnes D, Hughes RAC, Morris RW, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906.
3. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-1769.
4. La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 1994; 34:199-203.
5. Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998;50:1833-1836.
6. Tremlett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry 1998;65:362-365.
7. Ferry JJ, Horvath AM, Bekersky I, Heath EC, Ryan CF, Colburn WA. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol 1988;28:81-87.
8. Hayball PJ, Cosh DG, Ahem MJ, Schultz DW, Roberts-Thomson PJ. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol 1992;42:85-88.
9. Gambertoglio JG, Amend WJC, Benet LZ. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: A review. J Pharmacokinet Biopharm 1979;8:1-52.
10. Melby JC. Clinical pharmacology of systemic corticosteroids. Ann Rev Pharmacol Toxicol 1977;17:511-27.
11. Sellebjerg F, Frederiksen JL, Nielsen PM, Diesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998;51:529-534.
12. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-1220.
13. Ratto D, Alfaro C, Sipsey J, Glovsky MM, Sharma OP. Are intravenous corticosteroids required in status asthmaticus? JAMA 1988;260:527-529.
14. Smith MD, Ahem MJ, Roberts-Thomson PJ. Pulse steroid therapy in rheumatoid arthritis: Can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone? Ann Rheum Dis 1988;47:28-33.
15. Robson LS, Bain C, Beck S, Guthrie S, Coyte PC, O'Connor P. Cost analysis of methylprednisolone treatment of multiple sclerosis patients. Can J Neurol Sci 1998;25:222-229.
16. Meddings JB, Sutherland LR, Byles NI, Wallace JL. Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology 1993;104:1619-1626.
17. Sutherland LR, Verhoef M, Wallace JL, Van Rosendaal G, Crutcher R, Meddings JB. A simple, non-invasive marker of gastric damage: sucrose permeability. Lancet 1994;343:998-1000.
18. Maxton DG, Bjarnason I, Reynolds AP, Catt SD, Peters TJ, Menzies IS. Lactulose, 51 Cr-labeled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 as probe markers for assessment in vivo of human intestinal permeability. Clin Sci 1986;71:71-80.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
20. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996;110: 1395-1403.
21. Kiziltas S, Imeryuz N, Gurcan Y, et. al. Corticosteroid therapy augments gastroduodenal permeability to sucrose. Am J Gastroenterol 1998;93:2420-2425.
22. Spiro HM, Milles SS. Clinical and physiological implications of the steroid-induced peptic ulcer. N Engl J Med 1960;263: 286-294.
23. Dupuis RE. Solid organ transplantation. In: Young LY, Koda-Kimble MA (eds). Applied therapeutics: the clinical use of drugs. Vancouver, WA: Applied Therapeutics; 1995:33-35.